Furazabol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Furazabol
Skeletal formula of furazabol
Space-filling model of the furazabol molecule
Clinical data
Trade names Miotalon
Synonyms Androfurazanol; DH-245; Furazalon; Frazalon; Pirzalon; 17α-Methyl-5α-androsta-2,3-furazan-17β-ol; 17β-Hydroxy-17α-methyl-5α-androstano[2,3-c]-1',2',5'-oxadiazole; 17α-Methyl-5α-androstano[2,3-c][1,2,5]oxadiazol-17β-ol
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Biological half-life 4 hours[citation needed]
Excretion Urine
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
ECHA InfoCard 100.013.621
Chemical and physical data
Formula C20H30N2O2
Molar mass 330.47 g·mol−1
3D model (JSmol)
 NYesY (what is this?)  (verify)

Furazabol (INN, JAN) (brand name Miotalon), also known as androfurazanol, is a synthetic, orally active anabolic-androgenic steroid which has been marketed in Japan since 1969.[1][2][3][4] It is a 17α-alkylated derivative of dihydrotestosterone (DHT) and is closely related structurally to stanozolol, differing from it only by having a furazan ring system instead of pyrazole.[5] Furazabol has a relatively high ratio of anabolic to androgenic activity.[4] As with other 17α-alkylated AAS, it may have a risk of hepatotoxicity.[6] The drug has been described as an antihyperlipidemic and is claimed to be useful in the treatment of atherosclerosis and hypercholesterolemia,[5] but according to William Llewellyn, such properties of furazabol are a myth.[7]

References[edit]

  1. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 585–. ISBN 978-1-4757-2085-3. 
  2. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 475–. ISBN 978-3-88763-075-1. 
  3. ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 1725–. ISBN 978-0-8155-1856-3. 
  4. ^ a b Progress in Medicinal Chemistry. Elsevier. 1 January 1979. pp. 62–63. ISBN 978-0-08-086264-4. 
  5. ^ a b Fragkaki AG, Angelis YS, Koupparis M, Tsantili-Kakoulidou A, Kokotos G, Georgakopoulos C (2009). "Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor and to their anabolic and androgenic activities. Applied modifications in the steroidal structure". Steroids. 74 (2): 172–97. PMID 19028512. doi:10.1016/j.steroids.2008.10.016. 
  6. ^ Abbate V, Kicman AT, Evans-Brown M, McVeigh J, Cowan DA, Wilson C, Coles SJ, Walker CJ (2015). "Anabolic steroids detected in bodybuilding dietary supplements - a significant risk to public health". Drug Test Anal. 7 (7): 609–18. PMID 25284752. doi:10.1002/dta.1728. 
  7. ^ William Llewellyn (2007). Anabolics 2007: Anabolic Steroids Reference Manual. Body of Science. ISBN 978-0967930466.